Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2022-08-10 Interim / Quarterly Rep…
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
Form 10-Q for quarter ending June 30, 2022
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q filed with the U.S. Securities and Exchange Commission by Oramed Pharmaceuticals Inc. It explicitly states it is a 'Quarterly Report' for the period ended June 30, 2022, and contains comprehensive interim condensed consolidated financial statements, notes, and management's discussion and analysis. This fits the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-10 English
Form 10-Q for quarter ending June 30, 2022
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 2,000 characters) filed with the Israel Securities Authority. It explicitly states 'Attached hereto is a report on Form 10-Q' and provides a filename for the attachment. Per the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself. Therefore, it is classified as a Report Publication Announcement (RPA). Q2 2022
2022-08-10 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Sank Leonard
Director's Dealing Classification · 100% confidence The document is explicitly titled "FORM 4" and subtitled "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES". It is filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. This form is used by corporate insiders (directors, officers, or 10% owners) to report transactions in the company's stock. This type of filing relates directly to insider trading and executive share transactions, which corresponds to the 'Director's Dealing' category.
2022-08-10 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Sank Leonard
Director's Dealing Classification · 98% confidence The document explicitly states it is an 'Other Report or Announcement' under Israeli regulation and attaches a document titled '*Form 4 - Leonard Sank*'. Form 4 filings in the US context (and often referenced in international filings) relate to insider transactions, specifically reports of changes in beneficial ownership of securities by directors, officers, or 10% shareholders. Among the provided definitions, 'Director's Dealing' (Code: DIRS) is the most appropriate classification for insider transaction reports like Form 4, as it covers personal share transactions by company directors and executives.
2022-08-10 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2022
2022-08-10 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.